BioMendics advances its TAMES-02 trial of TolaSure™, a potential disease-modifying topical therapy for Epidermolysis Bullosa ...
Courtenay’s move represents a significant gain for McLaren, giving the Woking-based outfit access to insights gained over a ...
Space.com on MSN
Live long and loiter: Why NASA's ESCAPADE probes will wait a year in space before heading to Mars
"How do you get to Mars when the launch vehicle is not necessarily going to Mars?" ...
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaApproval based on global phase 3 program ...
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...
Gilead licensed Assembly Bio's long-acting HSV drugs after Phase 1b data showed antiviral activity and weekly oral dosing potential.
Sanofi and Regeneron receives Japanese marketing approval for Dupixent to treat bronchial asthma in children aged 6 to 11 years: Paris Wednesday, December 24, 2025, 11:00 Hrs [IST ...
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupix ...
Gilead Sciences and Assembly Biosciences have announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) ...
NASA’s ESCAPADE mission launched in 2025 to study Mars’ magnetic field and how solar wind has stripped away the planet’s atmosphere over time ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 13 Best Debt Free Dividend Stocks to Buy Now. On December ...
Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 receptors to enhance T cell-mediated cancer cell attack.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback